The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent
Executive Summary
Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond
You may also be interested in...
Merck Commercial Pilot Set To Fly Nationwide
Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said
Merck Commercial Pilot Set To Fly Nationwide
Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said
Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health
Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years